# Zhejiang JYSS Bio-Engineering Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zhejiang-jyss-bio-engineering-co

- Industry: Medical Devices & Equipment
- Headquarters: Hangzhou, China
- Website: www.jyssbio.com
- Total disclosed funding: $16M
- Latest round: Series B (Jan 4, 2022)
- Investors on record: 12

## About

Based in Beijing, China and established in 2014, Zhejiang JYSS Bio-Engineering Co., Ltd. is a developer that focuses on the research and development of disposable bioreactors and peripheral equipment. The company has 3,200 square meters of GMP consumables production workshop and 3,500 square meters of bioreactor production workshop. In 2018, the company officially entered the CDMO market.

The company engages in the research and development of disposable bioreactors. Its main products include microreactors, bioreactors, stirred bioreactors, samplers for disposable reactors, and liquid storage bags, etc. Torrent bioreactor is used for cell suspension culture and the development and production of recombinant proteins and other bioengineered products. The company's products are used in the biopharmaceutical industry.

## Funding rounds

- Series B, Jan 4, 2022, $16M — China International Capital Corporation, Sinowisdom, Xiamen C&D Group, Sinovac Biotech Co. Ltd., MPC, CICC Jia He Equity Investment Fund Management, Sherpa Healthcare Partners, CITIC Med Fund, Huatai International Private Equity Fund
- Series B, Jul 26, 2021 — Sinowisdom, CMB International Asset Management, MPC, Grandway Capital, Xiamen C&D Emerging Industry Equity Investment, Sherpa Healthcare Partners, CITIC Med Fund
- Series A, May 18, 2021 — Sinowisdom, MPC, Grandway Capital
- Angel, Oct 14, 2015 — Sinowisdom

## Investors

- Sinowisdom (https://capitalatlas.ai/funds/sinowisdom) — Angel, Series A, Series B
- MPC — Series A, Series B
- Grandway Capital (https://capitalatlas.ai/funds/grandway-capital) — Series A, Series B
- CMB International Asset Management (https://capitalatlas.ai/funds/cmb-international-asset-management) — Series B
- Xiamen C&D Emerging Industry Equity Investment (https://capitalatlas.ai/funds/xiamen-c-d-emerging-industry-equity-investment) — Series B
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series B
- CITIC Med Fund (https://capitalatlas.ai/funds/citic-med-fund) — Series B
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series B
- Xiamen C&D Group — Series B
- Sinovac Biotech Co. Ltd. — Series B
- CICC Jia He Equity Investment Fund Management — Series B
- Huatai International Private Equity Fund — Series B